These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 25274791)

  • 21. The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid-induced osteoporosis.
    Guañabens N; Gifre L; Peris P
    Curr Osteoporos Rep; 2014 Mar; 12(1):90-7. PubMed ID: 24488619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
    Toscani D; Bolzoni M; Ferretti M; Palumbo C; Giuliani N
    Front Immunol; 2018; 9():2467. PubMed ID: 30410490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.
    van Bezooijen RL; Roelen BA; Visser A; van der Wee-Pals L; de Wilt E; Karperien M; Hamersma H; Papapoulos SE; ten Dijke P; Löwik CW
    J Exp Med; 2004 Mar; 199(6):805-14. PubMed ID: 15024046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways.
    Krause C; Korchynskyi O; de Rooij K; Weidauer SE; de Gorter DJ; van Bezooijen RL; Hatsell S; Economides AN; Mueller TD; Löwik CW; ten Dijke P
    J Biol Chem; 2010 Dec; 285(53):41614-26. PubMed ID: 20952383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Physiological function of osteocytes].
    Ikeda K
    Clin Calcium; 2007 Oct; 17(10):1554-8. PubMed ID: 17906408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.
    Wijenayaka AR; Kogawa M; Lim HP; Bonewald LF; Findlay DM; Atkins GJ
    PLoS One; 2011; 6(10):e25900. PubMed ID: 21991382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Bromodomain Inhibitor
    Siegenthaler B; Ghayor C; Gjoksi-Cosandey B; Ruangsawasdi N; Weber FE
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30366476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating sclerostin associated with vertebral bone marrow fat in older men but not women.
    Ma YH; Schwartz AV; Sigurdsson S; Hue TF; Lang TF; Harris TB; Rosen CJ; Vittinghoff E; Eiriksdottir G; Hauksdottir AM; Siggeirsdottir K; Sigurdsson G; Oskarsdottir D; Napoli N; Palermo L; Gudnason V; Li X
    J Clin Endocrinol Metab; 2014 Dec; 99(12):E2584-90. PubMed ID: 25144629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.
    Atkins GJ; Rowe PS; Lim HP; Welldon KJ; Ormsby R; Wijenayaka AR; Zelenchuk L; Evdokiou A; Findlay DM
    J Bone Miner Res; 2011 Jul; 26(7):1425-36. PubMed ID: 21312267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.
    McDonald MM; Reagan MR; Youlten SE; Mohanty ST; Seckinger A; Terry RL; Pettitt JA; Simic MK; Cheng TL; Morse A; Le LMT; Abi-Hanna D; Kramer I; Falank C; Fairfield H; Ghobrial IM; Baldock PA; Little DG; Kneissel M; Vanderkerken K; Bassett JHD; Williams GR; Oyajobi BO; Hose D; Phan TG; Croucher PI
    Blood; 2017 Jun; 129(26):3452-3464. PubMed ID: 28515094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sclerostin expression in bone tumours and tumour-like lesions.
    Inagaki Y; Hookway ES; Kashima TG; Munemoto M; Tanaka Y; Hassan AB; Oppermann U; Athanasou NA
    Histopathology; 2016 Sep; 69(3):470-8. PubMed ID: 26896083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wnt signaling as a therapeutic target for bone diseases.
    Hoeppner LH; Secreto FJ; Westendorf JJ
    Expert Opin Ther Targets; 2009 Apr; 13(4):485-96. PubMed ID: 19335070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Sclerostin: a new biomarker of interest in nephrology].
    Pelletier S; Jean G; Fouque D;
    Ann Biol Clin (Paris); 2015; 73(3):305-13. PubMed ID: 26069067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sclerostin: recent advances and clinical implications.
    Honasoge M; Rao AD; Rao SD
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):437-46. PubMed ID: 25333305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteocyte regulation of bone mineral: a little give and take.
    Atkins GJ; Findlay DM
    Osteoporos Int; 2012 Aug; 23(8):2067-79. PubMed ID: 22302104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting sclerostin as potential treatment of osteoporosis.
    Papapoulos SE
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i119-22. PubMed ID: 21339215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Negative Association Between Sclerostin and INSL3 in Isolated Human Osteocytes and in Klinefelter Syndrome: New Hints for Testis-Bone Crosstalk.
    Di Nisio A; De Toni L; Rocca MS; Ghezzi M; Selice R; Taglialavoro G; Ferlin A; Foresta C
    J Clin Endocrinol Metab; 2018 May; 103(5):2033-2041. PubMed ID: 29452406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
    Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
    Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.
    Kogawa M; Wijenayaka AR; Ormsby RT; Thomas GP; Anderson PH; Bonewald LF; Findlay DM; Atkins GJ
    J Bone Miner Res; 2013 Dec; 28(12):2436-48. PubMed ID: 23737439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.
    Tu X; Rhee Y; Condon KW; Bivi N; Allen MR; Dwyer D; Stolina M; Turner CH; Robling AG; Plotkin LI; Bellido T
    Bone; 2012 Jan; 50(1):209-17. PubMed ID: 22075208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.